Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Juergen Wichmann"'
Publikováno v:
Biological Psychiatry. 91:S144
Autor:
Iyassu K. Sebhat, Sylvain Celanire, Stephan Schann, Silvia Gatti, Stanislas Mayer, Juergen Wichmann
Publikováno v:
Expert Opinion on Therapeutic Patents. 25:69-90
This review focuses on the medicinal chemistry efforts directed toward the identification of competitive and noncompetitive antagonists of glutamate at group II metabotropic glutamate receptors (mGluRII: mGlu2/3 and mGlu2). This class of compounds ho
Autor:
Silvia Gatti, Thomas Johannes Woltering, Frédéric Knoflach, Joerg Huwyler, Erwin Goetschi, Juergen Wichmann, Theresa M. Ballard
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:6969-6974
This study completes a series of papers devoted to the characterization of the non-competitive mGluR2/3 antagonist properties of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives with particular emphasis on derivatizations compatible with brain pen
Autor:
Andreas Bruns, Manfred Schneider, Sebastian H. Scharf, Lothar Lindemann, Porter Richard Hugh Phillip, Eric Prinssen, Anthony C. Harrison, Jean-Luc Moreau, Markus von Kienlin, Michael Honer, Juergen Wichmann, Thomas S. Kilduff, Liudmila Polonchuk, Christoph Funk, Stephen R. Morairty, Eric Vieira, Andreas Gloge, Will Spooren, Edilio Borroni, Sabine Kolczewski, Joseph G. Wettstein, Thomas Hartung, Basil Kuennecke, Neil Parrott, Axel Paehler, Georg Jaeschke, Urs Niederhauser
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 353(1)
Major depressive disorder (MDD) is a serious public health burden and a leading cause of disability. Its pharmacotherapy is currently limited to modulators of monoamine neurotransmitters and second-generation antipsychotics. Recently, glutamatergic a
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 311:645-651
Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one] was developed as a nonpeptide agonist of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptors, using bioassays at cloned receptors express
Autor:
Tomasz Dylag, Juergen Wichmann, Piotr Rafalski, Jolanta Kotlinska, Sylwia Talarek, Jerzy Silberring
Publikováno v:
NeuroReport. 14:601-604
The non-peptidergic opioid receptor-like 1 (ORL1, OP4) receptor ligand, Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4,5]decan-4-one], is a full agonist of the OP4 receptor. The aim of this study was to
Autor:
Maurizio Massi, Michela Biondini, Francois Jenck, Lorena Antonelli, Roberto Ciccocioppo, Juergen Wichmann
Publikováno v:
Psychopharmacology. 161:113-119
Rationale: (1S,3aS)-8-(2,3,3,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro 64-6198), a non-peptidic agonist for the opioid receptor-like1 (ORL1) receptor, exhibits anxiolytic properties in stressful conditions. Obje
Publikováno v:
Neuroreport. 13:451-454
The abuse liability of Ro 64-6198, an orphanin FQ (OFQ) receptor full agonist that exhibits anxiolytic properties, was evaluated using an unbiased conditioned place preference (CPP) paradigm in rats. As OFQ is structurally related to opioid peptides
Autor:
Geo Adam, Vincent Mutel, Sabine Kolczewski, Juergen Wichmann, Heinz Stadler, Thomas Johannes Woltering
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 9:2173-2176
Heterocyclic enol ethers of type 1 were studied with respect to the inhibition of 1S,3R-ACPD (10μM)-stimulated GTP γ35S binding on rat mGluR2 transfected cell membranes. The structure activity relationship with regard to the substitution pattern of
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 9:1573-1576
A series of 5H-thiazolo[3,2-a]pyrimidine derivatives 1 was studied with respect to the inhibition of 1S,3R-ACPD (10μM)-stimulated GTP γ 35 S binding on rat mGlu2 receptor transfected cell membranes. The influence of substituents at position 6 and 7